This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Taylor, N. P. Articles by Goodfellow, P. J. Search for Related Content PubMed PubMed Citation Articles by Taylor, N. P. Articles by Goodfellow, P. J.

MLH3 Mutation in Endometrial Cancer

¹ Department of Obstetrics and Gynecology, Division of Gynecologic Oncology; Departments of ² Pathology and Immunology and ³ Surgery, Washington University School of Medicine, St. Louis, Missouri; and ⁴ Laboratory Medicine and Pathology, Mayo Clinical College of Medicine, Rochester, Minnesota

Requests for reprints: Nicholas P. Taylor, Washington University School of Medicine, 4911 Barnes-Jewish Hospital Plaza, Maternity Building, 3rd Floor, St. Louis, MO 63110. Phone: 314-362-1977; Fax: 314-362-2893; E-mail: taylorni{at}wustl.edu.

MLH3 is a recently described member of the DNA mismatch repair gene family. Based on its interaction with the MutL homologue MLH1, it was postulated that MLH3 might play a role in tumorigenesis. Germ line and somatic mutations in MLH3 have been identified in a small fraction of colorectal cancers, but the role of MLH3 in colorectal cancer tumorigenesis remains controversial. We investigated MLH3's role in endometrial tumorigenesis through analysis of tumor and germ line DNA from 57 endometrial cancer patients who were at increased risk for having inherited cancer susceptibility. Patients with known MSH2 or MSH6 mutations were excluded as well as those who had MLH1-methylated tumors. Sixteen different variants were identified by single-strand conformational variant analysis. Of the 12 missense changes identified, three were somatic mutations. One patient had a germ line missense variant and loss of heterozygosity (LOH) in her tumor specimen. There was no evidence of MLH3 promoter methylation based on combined bisulfite restriction analysis. The identification of inherited missense variants, somatic missense mutations (present in 3 of 57 tumors), and LOH in the tumor from a patient with a germ line missense change suggest a role for MLH3 in endometrial tumorigenesis. (Cancer Res 2006; 66(15): 7502-8)